Oxytocin

Ion Peptide

$39.00

1 vial · vial

Oxytocin signals primarily through the oxytocin receptor (OXTR), a single G-protein-coupled receptor (GPCR) encoded on chromosome 3p25.3 in humans. OXTR couples predominantly to Gαq/11 signaling, activating phospholipase C, generating IP3 and DAG, raising intracellular calcium, and driving downstream effector responses depending on tissue. Oxytocin also has some cross-reactivity with the three vasopressin receptors (V1aR, V1bR, V2R), particularly at higher doses — a cross-reactivity that complicates interpretation of many oxytocin experiments because vasopressin has overlapping but distinct behavioral and autonomic effects.

Peripheral Actions (Classical Endocrine):

• Uterine Smooth Muscle: OXTR expression on myometrial cells rises dramatically in late pregnancy, making the uterus increasingly responsive to oxytocin and enabling the oxytocin-driven contractile cascade that produces labor. Peripheral oxytocin administration (Pitocin) during labor exploits this.
• Mammary Myoepithelial Cells: Oxytocin triggers contraction of myoepithelial cells surrounding milk-secreting alveoli, ejecting milk through the ducts during nursing. The milk-ejection reflex is one of the most reliable and dramatic oxytocin effects.
• Vascular Smooth Muscle: Oxytocin can produce modest vasodilation at low doses and vasoconstriction at high doses, contributing to minor blood pressure effects.
• Adipose Tissue: Peripheral OXTR expression on adipocytes contributes to modest lipolytic and glucose-homeostasis effects.
• Cardiac Tissue: OXTR expression in cardiomyocytes and cardiac fibroblasts suggests local cardiovascular roles, though clinical significance is uncertain.

Central Actions (Behavioral Neuropeptide): Oxytocin released centrally within the brain — not oxytocin released peripherally into blood — produces the social, emotional, and behavioral effects that have drawn popular attention. Key brain regions expressing OXTR include:

• Amygdala: Reduces threat-related responses; modulates fear learning and extinction. This is the primary mechanism for oxytocin's anxiolytic effects.
• Nucleus Accumbens and Ventral Tegmental Area: Mediates reward-related effects of social bonding. Particularly important for pair bonding and maternal attachment.
• Hippocampus: Modulates social memory and recognition.
• Prefrontal Cortex: Modulates top-down emotion regulation and social cognition.
• Hypothalamus (autoregulation): Oxytocin neurons receive feedback from their own release, contributing to pulse patterning.

The Blood-Brain Barrier Problem: This is the critical pharmacological issue with any peripheral oxytocin administration for central effects. Oxytocin is a polar peptide that crosses the intact blood-brain barrier poorly — estimates suggest less than 0.005% of peripheral oxytocin reaches brain parenchyma. Peripheral plasma oxytocin levels correlate weakly with CNS oxytocin concentrations, and in many situations the two are decoupled entirely. This means that subcutaneous or IV oxytocin produces powerful peripheral effects (uterine contraction, milk ejection) but uncertain central effects.

Intranasal Oxytocin and the "Nose-to-Brain" Debate: Most research and off-label use of oxytocin for behavioral effects relies on intranasal administration. The theoretical rationale is that peptides can reach the brain directly through the olfactory and trigeminal nerve pathways, bypassing the BBB. Empirical evidence for this route is mixed: some cerebrospinal fluid measurements suggest intranasal oxytocin does raise CSF oxytocin (suggesting central delivery), while other studies find no measurable CSF effect. Behavioral and fMRI studies consistently show some effects of intranasal oxytocin that suggest central activity, but the magnitude varies substantially across studies and individuals. The pharmacokinetic uncertainty is one reason oxytocin research has been less reproducible than for many other drugs.

Pharmacokinetics:

• Subcutaneous oxytocin peak plasma level: 10-15 minutes post-dose; plasma half-life: 3-5 minutes
• Intranasal oxytocin plasma rise: minimal (most of the dose is absorbed locally rather than systemically); duration of behavioral effects: 30-60 minutes for most assays, up to 2 hours in some contexts
• Oxytocin is degraded by multiple tissue peptidases including oxytocinase (placental), and plasma clearance is rapid

Individual Variation: OXTR has well-characterized genetic polymorphisms (rs53576 being the most studied) that modulate individual response to oxytocin. People with different OXTR genotypes appear to show different behavioral responses to exogenous oxytocin, though the effect sizes are small and not yet practically actionable at the individual level.

Comparison to Related Peptides:

• PT-141 (Bremelanotide): Acts at MC4R, drives central sexual arousal through a completely separate mechanism. Can be used alongside oxytocin for different aspects of sexual response — PT-141 more focused on physical arousal/desire, oxytocin more focused on emotional connection and bonding.
• Kisspeptin-10: Primary reproductive axis driver; also has limbic effects on desire but through a different receptor (KISS1R). Kisspeptin drives hormone production; oxytocin modulates social/emotional behavior at given hormone levels.
• Vasopressin (AVP): Sister peptide with overlapping and distinct effects, particularly pronounced on social behavior in males. Oxytocin's cross-reactivity with vasopressin receptors means some oxytocin effects may actually be vasopressin-mediated.

Oxytocin is a nine-amino-acid cyclic peptide hormone (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2) synthesized in magnocellular neurons of the hypothalamic paraventricular (PVN) and supraoptic nuclei (SON), then transported along axons to the posterior pituitary for release into systemic circulation. Vincent du Vigneaud synthesized oxytocin in 1953, becoming the first scientist to chemically synthesize a peptide hormone and earning the 1955 Nobel Prize in Chemistry for the achievement. The isolation and characterization of oxytocin marked the beginning of modern peptide pharmacology and established the template for all subsequent peptide drug development. Oxytocin's classical roles — uterine contraction during labor and milk ejection during breastfeeding — have been understood since the early 20th century and form the basis of its FDA approval as Pitocin (synthetic oxytocin) for labor induction and augmentation, postpartum hemorrhage control, and lactation support.

The story of oxytocin as something far more interesting than a reproductive hormone began in the 1990s, when researchers including Sue Carter, Thomas Insel, and Larry Young discovered that oxytocin released centrally in the brain (rather than peripherally through the posterior pituitary into blood) acts as a profound modulator of social behavior, pair bonding, trust, empathy, maternal behavior, and sexual response. Prairie vole studies showed that central oxytocin (and its sister peptide vasopressin) mediates the difference between monogamous and promiscuous mating strategies; human studies showed that intranasally administered oxytocin modulates trust, generosity, gaze patterns, and emotional recognition (Kosfeld et al., 2005, Insel & Young, 2001). This "social neuropeptide" framing generated enormous scientific and popular interest and motivated clinical trials exploring oxytocin for autism spectrum disorders, post-traumatic stress disorder, social anxiety, schizophrenia-related social dysfunction, and relationship therapy applications.

Results from those clinical trials have been more nuanced than the early excitement suggested. Large randomized controlled trials in autism have shown mixed-to-disappointing results (Sikich et al., 2021 NEJM). The initial Kosfeld "trust" finding and related social cognition effects have been difficult to replicate consistently, leading to a reckoning about methodological issues in the early oxytocin literature (Nave et al., 2015 meta-analysis). What has held up is that oxytocin does produce subtle, context-dependent effects on social and emotional processing in some people under some conditions — but it is not the universal love-and-trust drug that early popular science coverage sometimes implied. The pharmacology is more sophisticated than a simple "love hormone" narrative allows.

In current clinical practice, oxytocin has well-established approval for obstetric uses (Pitocin IV for labor, Syntocinon nasal spray for milk letdown in some markets). Off-label and grey-market use of oxytocin — typically via compounded nasal spray or subcutaneous injection — is pursued for three main reasons: (1) improving sexual and emotional connection with partners, which is the most common recreational motivation and the one with the most credible (if limited) evidence base; (2) managing social anxiety, autism-spectrum social challenges, or post-traumatic stress symptoms under self-directed protocols; and (3) adjunctive use during couples therapy, psychotherapy, or other relational contexts where the modest pro-social effects may facilitate the therapeutic process. None of these off-label uses is supported by rigorous efficacy evidence comparable to what exists for approved indications, and the intranasal route that most community use relies on has significant questions about how much centrally active oxytocin actually reaches the brain after nasal administration (Leng & Ludwig, 2016).

This entry covers what oxytocin does biologically, what clinical evidence exists for its various uses, and the practical realities of off-label oxytocin use including route-of-administration uncertainties, duration of effect, and limitations. Unlike many peptides covered here, oxytocin has a genuinely large scientific literature — several thousand published human studies — but separating signal from noise in that literature requires careful reading. Cross-links to related compounds include PT-141 (Bremelanotide) for central sexual arousal effects through an independent (melanocortin) mechanism, and Kisspeptin-10 for reproductive axis and desire effects through yet another distinct mechanism.

IUPAC Name

Oxytocin

CAS Number

50-56-6

Molecular Formula

C43H66N12O12S2

Molecular Mass

1007.19 g/mol

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Interaction Matrix

Get Oxytocin Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it. Current lowest: $34.99

Related Compounds

Related Articles

Ion Peptide

$39.00

Data Completeness

Research Credibility